Physician profile
Thomas E Craig
NPI 1720163066
$1,253.36
in general payments reported to CMS, 2019-2025
17 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $221 · 2021: $29.13 · 2022: $91.72 · 2024: $203 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.47 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $226.34 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $126.87 | 2019-2024 | Ultomiris |
| Nxstage Medical, INC. | $121.68 | 2022-2024 | |
| Amgen INC. | $116.24 | 2019 | |
| Mallinckrodt Enterprises LLC | $116.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $95.62 | 2024-2025 | |
| Vifor Pharma, INC. | $82.13 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $71.24 | 2020-2025 | Acthar |
| Akebia Therapeutics INC | $67.11 | 2020-2024 | Vafseo |
| Fresenius USA Marketing, INC. | $57.70 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.63 | 2022 | |
| Opko Pharmaceuticals, LLC | $37.11 | 2020-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.26 | 2025 | Jynarque |
| Octapharma USA, INC. | $20.34 | 2024 | Octagam Immune Globulin (Human) |
| Travere Therapeutics, INC. | $19.15 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $18.06 | 2024 | Lupkynis |
| Ardelyx, INC. | $17.82 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.